Rubin: FDA helped Merck figure out how to channel science into regulatory approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login